By Abigail Townsend
Date: Wednesday 20 Oct 2021
(Sharecast News) - Biogen raised its full-year earnings guidance on Wednesday, despite weak sales of breakthrough Alzheimer's drug Aduhelm.
Currency | US Dollars |
Share Price | $ 139.31 |
Change Today | $ 0.19 |
% Change | 0.14 % |
52 Week High | $206.18 |
52 Week Low | $118.84 |
Volume | 1,199,214 |
Shares Issued | 145.80m |
Market Cap | $20,311m |
RiskGrade | 259 |
Strong Buy | 7 |
Buy | 6 |
Neutral | 21 |
Sell | 1 |
Strong Sell | 0 |
Total | 35 |
Time | Volume / Share Price |
16:00 | 138,045 @ $139.31 |
15:59 | 100 @ $139.26 |
15:59 | 100 @ $139.27 |
15:59 | 300 @ $139.33 |
15:59 | 100 @ $139.31 |
You are here: research